Elevated serum interferon-γ in atopic asthma correlates with increased airways responsiveness and circadian peak expiratory flow variation

N.H.T. ten Hacken*, Y. Oosterhoff*, H.F. Kauffman†, L. Guevarra, T. Satoh§, D.J. Tollerud†, D.S. Postma*


ABSTRACT: Interleukin (IL)-4, IL-5 and interferon (IFN)-γ are thought to play an important role in chronic airway inflammation in asthmatic subjects. Increased airways responsiveness and nocturnal airway obstruction are important clinical manifestations of asthma. The aim of this study was to investigate whether IL-4, IL-5 and IFN-γ values are elevated in atopic asthma and correlate with its clinical manifestations.

Serum IL-4, IL-5 and IFN-γ levels of 17 atopic asthmatics and eight nonatopic healthy subjects were determined at 16:00 and 04:00 h by a chemiluminescence enzyme-linked immunosorbent assay (ELISA) method. The clinical manifestation of asthma was determined by assessment of the degree of airway obstruction, airways responsiveness to methacholine and severity of nocturnal airway obstruction, defined as the mean circadian (16:00–04:00 h) peak expiratory flow (PEF) variation.

Serum IL-4, IL-5 and IFN-γ levels were significantly higher in asthmatic subjects as compared to healthy controls, both at 16:00 and 04:00 h. In asthmatic subjects serum IFN-γ at both time points correlated significantly with the provocative concentration of methacholine causing a 20% fall in forced expiratory volume in one second (PC20meth) (ρ = 0.55) and with the mean 16:00–04:00 h PEF variation (ρ = 0.53). In contrast, no relationship was found between the levels of IL-4 and IL-5 and the parameters of clinical manifestation of asthma.

The results suggest that the serum interferon-γ level is a reflection of the severity of airway inflammation in atopic asthma. More studies are needed to detect the cellular sources and to clarify the exact roles of interferon-γ and other pro-inflammatory cytokines in asthma.


Asthma is characterized as a chronic inflammatory disease of the airways. The presence of inflammation is associated with airways hyperresponsiveness to inhaled stimuli and the development of increased nocturnal airway obstruction [1]. Many different inflammatory cells are involved in asthma, including activated T-helper lymphocytes, eosinophils, mast cells and macrophages. These cells can synthesize and release cytokines, which are increasingly recognized to be important in chronic inflammation and play a critical role in orchestrating the inflammatory response. In this respect, emphasis has been laid on an imbalance between type 1 T-helper (Th1) and type 2 T-helper (Th2) cytokines in the development of allergic inflammation. Elevated levels of interleukin (IL)-4, an essential co-factor for immunoglobulin E (IgE) production, and IL-5, responsible for the final differentiation, activation and recruitment of eosinophils [2], have been found in serum of patients with asthma [3–6]. Interferon-γ (IFN-γ) on the other hand inhibits Th2 mediated inflammation in atopic diseases. Both elevated [7, 8] and nonelevated [4, 6] serum levels of IFN-γ have been reported in asthmatic patients.

Since little is known about the direct relationship between cytokine levels and the clinical manifestation of atopic asthma (the degree of airway obstruction, airways responsiveness to methacholine and severity of nocturnal airway obstruction, defined as mean 16:00–04:00 h peak expiratory flow (PEF) variation), we determined the concentrations of IL-4, IL-5 and IFN-γ in serum and bronchoalveolar lavage (BAL) fluid from subjects with atopic asthma and healthy controls [1]. The asthmatic subjects participating in this study were selected in order to obtain a wide range of circadian PEF variations, and measurements were performed at 16:00 and 04:00 h.

Materials and methods

Subjects

Asthmatic subjects (nonsmokers) were selected on the basis of: 1) a history consistent with the diagnosis of...
asthma; 2) atopy, *i.e.* positive intracutaneous tests against house-dust mite or two of 12 other tested common aeroallergens, expressed as histamine equivalent wheal size (HEWS) ≥0.7 [9]; 3) forced expiratory volume in one second (FEV1) >1.5 L, and >70% predicted; postbronchodilator FEV1 (salbutamol 400 µg using a spacerhaler) >10%; 4) provocative concentration of methacholine bromide causing a 20% fall in FEV1 (PC20,meth) <10% fall in FEV1 after inhalation of 9.8 mg·mL⁻¹ methacholine bromide); and 4) no upper respiratory infection(s) within 1 month before the study.

Non-smoking healthy volunteers had: 1) no history of lung disease or allergy; 2) no atopy, *i.e.* negative intracutaneous tests against 12 common aeroallergens (HEWS <0.7); 3) no airways hyperresponsiveness to methacholine (<10% fall in FEV1 after inhalation of 9.8 mg·mL⁻¹ methacholine bromide); and 4) no upper respiratory infection(s) within 1 month before the study.

**Study design**

IL-4, IL-5 and IFN-γ were analysed in serum and BAL fluid, obtained during a prospective study on nocturnal asthma, published previously [1]. In this study FEV1, blood sampling and bronchoscopy were performed at 16:00 h (or 04:00 h), and repeated 7–14 days later at 04:00 h (or 16:00 h).

Three days before the first investigation, bronchodilators (β₂-agonists or ipratropium bromide) were withheld and PEF values were recorded with a mini-Wright peak flow meter at 08:00, 12:00, 16:00, 20:00, 24:00 and 04:00 h. The 16:00–04:00 h PEF variation was calculated as: (16:00–04:00 h value)/mean of six daily measurements. The mean 16:00–04:00 h PEF variation was defined as: (16:00–04:00 h value)/mean of six daily measurements. The measurement was calculated as:

**Processing of BAL fluid.** The BAL fluid recovered from the first two 20 mL aliquots of PBS instilled was processed separately and used for analysis of cytokines. The lavage fluid was filtered through a 100 µm pore filter of a venous infusion system (Curapharm, Medica B.V., Hospital Supplies, the Netherlands) to remove mucus, and centrifuged at 400×g at 4°C for 5 min. The BAL supernatant was decanted from the cell pellet and stored at -80°C until further determination.

**Processing of blood samples.** Serum was acquired after coagulation of venous blood for 1 h at room temperature. The supernatant was centrifuged twice for 10 min at 2000×g and stored at -80°C until analysis. Serum total IgE was determined by a fluoro-immunoassay (Kabi Pharmacia, Woerden, the Netherlands).

**Determination of cytokines in serum and BAL fluid.** Levels of IL-4, IL-5 and IFN-γ were determined by a chemiluminescence enzyme-linked immunosorbent assay (ELISA) in the laboratory of the Department of Environmental and Occupational Health at the University of Pittsburgh. Ninety-six-well opaque microtitre plates (Microlite 1, Dynatech, Chantilly, VA, USA) were coated with 100 µL of diluted purified anti-cytokine monoclonal antibody (capture moAb; 1–4 µg·mL⁻¹) in 0.1M sodium bicarbonate (NaHCO₃) coating buffer. Plates were incubated overnight at 4°C, generally with gentle shaking, subsequently washed with 300 µL well⁻¹ of PBS-Tween and blotted dry. Wells were blocked with 300 µL well⁻¹ of 2.5 % (w/v) bovine serum albumin (BSA)/PBS-Tween and washed with PBS-Tween. Recombinant standards and samples (diluted appropriately in 0.5-1% BSA/PBS-Tween), were added (100 µL well⁻¹), in duplicate or triplicate wells and incubated overnight at 4°C with gentle shaking. Plates were then washed with PBS-Tween, and 100 µL well⁻¹ biotinylated anti-cytokine monoclonal antibody (detecting moAb; 1–4 µg·mL⁻¹) in 0.1M sodium bicarbonate (NaHCO₃) coating buffer. Plates were incubated overnight at 4°C with gentle shaking. Plates were then washed with PBS-Tween, and 100 µL well⁻¹ biotinylated anticytokine monoclonal antibody (detecting moAb; 1–4 µg·mL⁻¹) in 0.1M sodium bicarbonate (NaHCO₃) coating buffer. Plates were incubated overnight at 4°C with gentle shaking. Plates were incubated overnight at 4°C with gentle shaking. The chemiluminescence ELISA assays have been validated for accuracy and sensitivity using recombinant human cytokines, including World Health Organization (WHO) standard recombinant cytokines. WHO standards included: recombinant Human IFN-γ (Catalogue No. Gg23-901-530; National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD, USA); recombinant human IL-4 and recombinant human IL-5 (88/656 and 90/586, respectively; National Institute for Biological Standards and Control, Hertfordshire, UK). The assays were extensively tested using media and human serum samples spiked with mixtures of known quantities of recombinant cytokines. Each assay is highly specific for the cytokine of interest, with no detectable cross-reactivity with other cytokines. These studies confirmed the quality assurance data provided by the manufacturers of the monoclonal antibody pairs.
Using this method, detection levels of IL-4, IL-5 and IFN-γ in serum were 5, 2.5 and 2.5 pg·mL⁻¹, respectively. Detection levels of IL-4, IL-5 and IFN-γ in BAL-fluid were 10, 5 and <1.25 pg·mL⁻¹, respectively.

Data analysis

All analyses were performed with the Statistical Products and Service Solutions (SPSS)/PC 5.01 software package (SPSS Inc., Chicago, IL, USA). A p-value of less than 0.05 was considered statistically significant. Undetectable values were set at the lowest detection levels. The Mann-Whitney U-test was used to compare cytokine levels between groups, and Wilcoxon's matched sign rank test was applied for within-group analysis. Correlations between cytokine concentrations and other parameters were made using Spearman’s rank correlation tests.

Results

Eight healthy volunteers and 17 asthmatic subjects participated in this study. The 12 male and 13 female subjects were equally distributed between the two groups (Chi-squared, p=0.43). Differences in lung function and other characteristics between the asthmatic and healthy subjects are shown in table 1.

Serum levels of IL-4, IL-5 and IFN-γ were detectable in all asthmatic subjects and in most healthy controls (fig. 1). Median levels of IL-4, IL-5 and IFN-γ in the asthmatic subjects were significantly higher than in the healthy controls, both during the day (fig. 1) and night (data not shown). Levels of IL-4 and IL-5 showed a positive correlation with each other in the asthmatic subjects (rho=0.81, p<0.001), as did levels of IL-4 and IFN-γ (rho=0.62, p<0.001). The correlations between serum cytokines and clinical parameters in the asthmatic patients are shown in table 2. Serum IFN-γ at both time points correlated significantly with PC20,meth (fig. 2a) and 16:00–04:00 h PEF variation (fig. 2b). Otherwise, no significant correlations were found.

The median IFN-γ level in serum of asthmatic patients was significantly higher during the night as compared to the day: 56 (range 16–223) pg·mL⁻¹ at 04:00 h versus 46 (range 15–128) pg·mL⁻¹ at 16:00 h (p<0.05). Day-night changes of IFN-γ in the asthmatic subjects did not correlate with day-night changes in PEF or FEV1% pred. The median IFN-γ levels in healthy subjects were not significantly different between day and night and there were no significant differences between day and night in IL-4 and IL-5 levels in healthy and asthmatic subjects (data not shown).

BAL fluid levels of IL-4, IL-5 and IFN-γ were frequently below the level of detection: in the eight healthy volunteers, levels below the detection limit were found in none, four and eight of the subjects, respectively, and six, 12 and 14 of the 17 asthmatic subjects, respectively (16:00 h). Median (range) values of IL-4, IL-5 and IFN-γ in the healthy volunteers were: 17.5 (10–71), 6 (5–24) and <1.25 (<1.25–0.8) pg·mL⁻¹, respectively (16:00 h). Median (range) values of IL-4, IL-5 and IFN-γ in the asthmatic subjects were: 14 (10–442), 5 (5–143) and <1.25 (<1.25–0.8) pg·mL⁻¹, respectively (16:00 h). Median BAL fluid levels of IL-4, IL-5 and IFN-γ were not significantly different between healthy and asthmatic subjects at the different time points.

Table 1. – Characteristics of the participating subjects

<table>
<thead>
<tr>
<th></th>
<th>Healthy</th>
<th>Asthmatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects n</td>
<td>8</td>
<td>17</td>
</tr>
<tr>
<td>Male/Female</td>
<td>4/4</td>
<td>8/9</td>
</tr>
<tr>
<td>Age yrs</td>
<td>24.5</td>
<td>(210–44)</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>(18–41)</td>
</tr>
<tr>
<td>Positive skin tests</td>
<td>0</td>
<td>6 (2–8)</td>
</tr>
<tr>
<td>Total serum IgE IU·L⁻¹</td>
<td>39</td>
<td>333</td>
</tr>
<tr>
<td>Blood eosinophils 16 h</td>
<td>88</td>
<td>264</td>
</tr>
<tr>
<td></td>
<td>(22–297)</td>
<td>(44–605)*</td>
</tr>
<tr>
<td>10 cells·L⁻¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 16 h % pred</td>
<td>105</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>(88–125)</td>
<td>(68–114)*</td>
</tr>
<tr>
<td>PC20,meth mg·mL⁻¹</td>
<td>&gt;9.8</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td>(0.04–1.88)</td>
<td></td>
</tr>
<tr>
<td>16:00–04:00 h PEF variation</td>
<td>6.9</td>
<td>14.9</td>
</tr>
<tr>
<td></td>
<td>(4.3–8.0)</td>
<td>(1.7–37.3)*</td>
</tr>
</tbody>
</table>

Values are expressed as medians, and range in parentheses. *: p<0.05; **: p<0.001, versus healthy controls. The values of the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20,meth) were not compared statistically since they were part of the selection criteria. IgE: immunoglobulin E; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow.

Table 2. – Correlations between serum cytokines (16:00 h) and important clinical parameters of asthma

<table>
<thead>
<tr>
<th></th>
<th>IL-4</th>
<th>IL-5</th>
<th>IFN-γ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total serum IgE</td>
<td>-0.17</td>
<td>-0.34</td>
<td>-0.01</td>
</tr>
<tr>
<td>Blood eosinophils</td>
<td>0.29</td>
<td>0.28</td>
<td>0.27</td>
</tr>
<tr>
<td>FEV1 % predicted</td>
<td>-0.29</td>
<td>-0.38</td>
<td>-0.33</td>
</tr>
<tr>
<td>PC20,meth</td>
<td>-0.21</td>
<td>-0.06</td>
<td>-0.55*</td>
</tr>
<tr>
<td>16:00–04:00 h PEF variation</td>
<td>0.29</td>
<td>0.06</td>
<td>0.53*</td>
</tr>
</tbody>
</table>

Values are correlation coefficients (Spearman’s rank test). *: p<0.05. Only the 16:00 h values are presented because the 04:00 h values were virtually identical. The same correlations were significant. IL: interleukin; IFN-γ: interferon-γ. For further definitions, see legend to table 1.
or between day and night values within the healthy and asthmatic groups. The BAL fluid levels of IL-4, IL-5 and IFN-γ did not correlate with the PC20 values, 16:00–04:00 h PEF variation or FEV1% pred.

Discussion

This study demonstrated that the median levels of serum IL-4, IL-5 and IFN-γ were significantly higher in the asthmatic group than in the healthy control group. Moreover, elevated serum levels of IFN-γ in subjects with atopic asthma were correlated with an increased airways responsiveness to methacholine and a larger 16:00–04:00 h PEF variation. In contrast, no relationship was found between serum levels of IL-4 and IL-5 and the parameters of clinical manifestation of asthma. Median levels of IL-4 and IL-5 in BAL fluid were not different between asthmatic and healthy subjects, whereas the levels of IFN-γ in BAL fluid were mainly below the level of detection with the method used.

The finding of higher serum IFN-γ levels are in line with the results of two other studies. Sato et al. [8] showed a higher mean plasma concentration of IFN-γ in patients with mite-sensitive asthma as compared to healthy controls. In addition, Corrigan et al. [7] showed that serum IFN-γ levels were elevated in patients with acute severe asthma and normalized upon treatment. Unlike the study of Corrigan et al. [7] our patients did not suffer from a viral or bacterial airway infection as a potential cause for increased IFN-γ production. The relationships between higher serum IFN-γ levels and increased nocturnal airway obstruction and increased airways responsiveness to methacholine rather suggest that the increased serum IFN-γ levels reflect an ongoing inflammatory process that determines the clinical manifestations of airway disease in atopic asthma. In ovalbumin-challenged mice it has been found that treatment with antibodies to IFN-γ selectively abolished development of airway hyperresponsiveness, whereas antibodies to IL-5 inhibited BAL eosinophilia [12], suggesting that INF-γ and IL-5 act on different phenomena. It can also be produced by other cell types, including type 0 T-helper (Th0) and CD8 lymphocytes, granulocytes, eosinophils and macrophages, present in the bronchial wall, peripheral blood and other body compartments. It has been shown that the in vitro production of IFN-γ by peripheral blood mononuclear cells is not increased in patients with asthma [4, 6, 15]. We assume that the increased IFN-γ values found in the serum of the present patients originated from cellular sources outside the vascular compartment. Interestingly, Kiss et al. [15] recently demonstrated a higher percentage of IFN-γ producing T-cells in the BAL fluid of asthmatic subjects as compared to atopic and nonatopic controls. On the other hand, Ying et al. [16] showed a significantly lower number of CD3 and CD68 positive cells encoding messenger ribonucleic acid (mRNA) for IFN-γ in the bronchial biopsies of atopic asthmatics as compared to healthy controls, but no information was presented on production of the protein. Up to now, no attention has been paid to cytokine signals in granulocytes and CD8 positive cells, nor to cytokine signals in the epithelial airway mucosa. This leaves open the possibility of an increased IFN-γ produc-

Fig. 2. – Correlation between serum interferon-γ levels (pg·mL−1) at 16:00 h and: a) PC20,meth values; and b) 16:00–04:00 h peak expiratory flow (PEF) variation, in 17 subjects with atopic asthma. For further definition, see legend to table 1.
tion by inflammatory cells in the superficial layer of the bronchial wall.

In contrast to other studies [3, 6], serum IL-4 levels did not correlate with IgE and serum IL-5 did not correlate with blood eosinophils. We have no clear explanation for our negative findings. It can be hypothesized that the indices of IgE-mediated inflammation are obscured by other inflammatory processes that are more related with the clinical manifestation of asthma.

This study also demonstrated higher levels of IFN-γ in the serum at night than during the day in the asthmatic patients. The rise of IFN-γ levels did not, however, correlate with day-night changes in PEF or FEV₁. Thus, no evidence was found to suggest that increased nocturnal airway narrowing in atopic asthma is associated with increased cytokine production at night. This finding is in line with previous observations, showing that an increased nocturnal airway obstruction merely occurs in asthmatic subjects with signs of increased inflammatory cellular activation in the airways at daytime [17].

In conclusion, elevated serum levels of IFN-γ in subjects with atopic asthma were correlated with an increased airways responsiveness to methacholine and a larger 16:00–04:00 h peak expiratory flow variation. In contrast, no relationship was found between the levels of interleukin-4 and interleukin-5 and the parameters of clinical manifestation of asthma. The results suggest that the serum interferon-γ level can be regarded as a reflection of the severity of airway inflammation in atopic asthma. Up to now, the origin of serum interferon-γ is unclear. More studies are needed to detect the cellular sources and to clarify the exact roles of interferon-γ and other pro-inflammatory cytokines in asthma.

References